跳至主要内容
临床试验/NCT02025491
NCT02025491已完成3 期

Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis

Hospital Universitário Professor Edgard Santos1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Definitive cure

研究概览

简要总结

Disseminated leishmaniasis (DL) is an emerging and severe form of leishmaniasis, with increasing prevalence in Bahia, Brasil. It is characterized by multiple acneiform, papular and ulcerated lesions localized on the face, chest, abdomen and extremities. The number of lesions ranges from 10 to hundreds, and mucosal disease has been documented in more than 40% of the cases.

DL is a hard to cure disease and therapeutic failure with pentavalent antimony has been documented in up to 70% of the cases caused by L. braziliensis in the endemic area of Corte de Pedra, Bahia. The majority of DL patients need several courses of antimony or the use of high dose of Amphotericin B desoxicolate to cure. Therefore DL patients are exposed to relevant drug toxicity, high morbidity due to a long lasting disease, with an important socio-economic impact. Our hypothesis is that liposomal Amphotericin B has a higher cure rate than historic cure rates of pentavalent antimony in the treatment of disseminated leishmaniasis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
14 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • a) clinical diagnosis of Disseminated Leishmaniasis according to case definition; b) illness duration of less than three months, c) parasite identification by culture or polymerase chain reaction methods, d) no previous treatment for leishmaniasis.

排除标准

  • a) immunodeficiency or antibodies to HIV, b) pregnancy or patients not willing or unable to use contraceptives during and 3 months after the end of therapy c) ALT, AST ≥3x normal reference values, creatinine and BUN ≥1.5x normal reference values, d) any evidence of serious underlying disease (cardiac, renal, hepatic, or pulmonary) including serious infection other than DL.

研究组 & 干预措施

Liposomal Amphotericin

Experimental

Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.

干预措施: Liposomal Amphotericin B (Drug)

结局指标

主要结局

Definitive cure

时间窗: 3 months after treatment

Definitive cure at 3 months after the end of treatment is defined as complete epithelialization of all ulcers and complete disappearance of inflammatory infiltrations from all lesions.

次要结局

  • Toxicity(During the 7 to 15 days of treatment)

研究者

发起方
Hospital Universitário Professor Edgard Santos
申办方类型
Other
责任方
Principal Investigator
主要研究者

Paulo Roberto Lima Machado

MD PhD

Hospital Universitário Professor Edgard Santos

研究点 (1)

Loading locations...

相似试验